Hypoxanthine-arabinoside Pharmacokinetics After Adenine Arabinoside Administration to a Patient with Renal Failure
Overview
Affiliations
Hypoxanthine arabinoside pharmacokinetics were measured during an adenine arabinoside continuous intravenous infusion and during hemodialysis in a patient with renal failure. Therapeutic guidelines for adenine arabinoside in renal failure are provided based on an elimination half-life of 4.7 h and a plasma clearance of 87.9 ml/min for the hypoxanthine metabolite.
Comparative pharmacokinetics of antiviral nucleoside analogues.
Morse G, Shelton M, ODonnell A Clin Pharmacokinet. 1993; 24(2):101-23.
PMID: 8453821 DOI: 10.2165/00003088-199324020-00002.
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
Lee C, Marbury T Clin Pharmacokinet. 1984; 9(1):42-66.
PMID: 6362952 DOI: 10.2165/00003088-198409010-00003.
Reines E, Gross P Med Clin North Am. 1988; 72(3):691-715.
PMID: 3280914 PMC: 7131553. DOI: 10.1016/s0025-7125(16)30766-0.
Guide to drug dosage in renal failure.
Bennett W Clin Pharmacokinet. 1988; 15(5):326-54.
PMID: 3060292 DOI: 10.2165/00003088-198815050-00005.
MCCANN W, Hall L, SILER W, Barton N, Whitley R Antimicrob Agents Chemother. 1985; 28(2):265-73.
PMID: 2423028 PMC: 180230. DOI: 10.1128/AAC.28.2.265.